MTSL Issue 817

 Comments Off on MTSL Issue 817
Dec 202015
 
MTSL Issue 817

Issue No. 817 (dated 12/17/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #ALKS #MDCO #NKTR #NVAX #OGXI #PCRX SGMO #ZIOP

MTSL Issue 816

 Comments Off on MTSL Issue 816
Dec 062015
 
MTSL Issue 816

Issue No. 816 (dated 12/3/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #BMRN #XON #MDCO #NKTR #NVAX #OGXI #SGMO #ZIOP

MTSL Issue 815

 Comments Off on MTSL Issue 815
Nov 152015
 
MTSL Issue 815

Issue No. 815 (dated 11/12/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #ACAD, #FPRX, #INCY, #ISIS, #MDCO, #NKTR, #NVAX, #OGXI, #XON

Novavax Update (8-11-15)

 Comments Off on Novavax Update (8-11-15)
Aug 112015
 
Novavax Update (8-11-15)

Special Update – NVAX – Positive Phase II RSV Vaccine Data De-Risks The Crown Jewel – Raising Buy Limit and Target Price – In the large Phase II trial, NVAX has delivered excellent RSV F protein vaccine data in the most difficult-to-treat elderly population (>60 years old). The study is the first ever demonstration of efficacy of an active RSV vaccine in humans, read more…

‘Access to Management’ Conference Call with Novavax (12-19-14)

 Comments Off on ‘Access to Management’ Conference Call with Novavax (12-19-14)
Dec 232014
 
'Access to Management' Conference Call with Novavax (12-19-14)

(for subscribers only) Listen to the ‘Access to Management’ Conference Call we had with the Novavax Management Team on Friday, December 19, 2014 where we discussed what’s in the Novavax pipeline, offered a brief R&D Summary and had a Q&A session with subscribers.        

Novavax Update (10-27-14)

 Comments Off on Novavax Update (10-27-14)
Jun 052014
 
Novavax Update (10-27-14)

BioInvest News for NVAX – Novavax Enters Ebola Vaccine Race with a Bang – After remaining mum during the recent Ebola hype-fest, NVAX waited until they had truly legitimate news to report.  This weekend, the company released positive preclinical Ebola vaccine data in guinea pigs at the 8th Vaccine and ISV Conference in Philadelphia (10/26). […]

Apr 282014
 
Novavax Update (4-28-14)

NVAX – RSV Vaccine Dose Confirmatory Trial Highly Successful – After the close, Novavax announced positive top-line safety and immunogenicity data from its RSV-F protein nanoparticle vaccine candidate in a Phase 2 clinical trial in 720 women of childbearing age.  The randomized, blinded, placebo-controlled Phase 2 study was designed to evaluate the immunogenicity and safety […]

Novavax Update (1-9-14)

 Comments Off on Novavax Update (1-9-14)
Jan 122014
 
Novavax Update (1-9-14)

Novavax (NVAX) – Stocks of biotechnology companies that reach major inflection points tend to outperform for several years.  After a major leap forward in 2013, NVAX is executing its clinical plan with a clearly defined and risk-adjusted strategy.  NVAX’s addressable markets are approximately $4 billion per year.  Global flu vaccines represent a $3 billion market […]

Novavax Update (11-14-13)

 Comments Off on Novavax Update (11-14-13)
Nov 142013
 
Novavax Update (11-14-13)

Special Update – NVAX – Novavax H7N9 Published In The NEJM – First Industry Vaccine For H7N9 Elicits Major Protective Immune Response In Blinding Speed – In a prestigious surprise, Novavax released its Phase I trial of 284 subjects injected with the H7N9 flu virus vaccine – published in the most recent online edition of […]

Novavax Update (7-31-13)

 Comments Off on Novavax Update (7-31-13)
Jul 312013
 
Novavax Update (7-31-13)

NVAX – ISCONOVA DEAL SOUND STRATEGIC MOVE – BUY NVAX AHEAD OF CLOSING – BUY UNDER 3 1/2, TARGET PRICE 8.  Novavax announced today that as of yesterday (the initial Offer deadline), approximately 97.4% of the common stock and 100% of the warrants issued by Isconova (ISO, www.isconova.com), respectively, have been tendered. As a result, […]

Novavax Update (7-5-13)

 Comments Off on Novavax Update (7-5-13)
Jul 052013
 
Novavax Update (7-5-13)

NVAX – Novavax Announces Positive Results of RSV F Protein Vaccine in Elderly – Paving Way For The Ultimate INFLUENZA/RSV Combination Vaccine  – Raising BUY LIMIT and TARGET PRICE – The successful trial exhibited evidence of a real vaccine across the board. In 220 patients, the F-Protein vaccine: a) was well-tolerated without any vaccine-related serious […]

Novavax Update (4-25-13)

 Comments Off on Novavax Update (4-25-13)
Apr 262013
 
Novavax Update (4-25-13)

NovaVax – Why VLPs are VIPs. The key to the NVAX vaccine platform technology is the use of virus-like particles (VLPs) to safely deliver key immune-identifying proteins to the body.  Importantly, proof of concept is in place as VLPs are recombinant particles similar to currently marketed vaccines.  Merck’s Recombivax HB and GSK’s Engerix B are recombinant […]

Novavax Update (4-2-13)

 Comments Off on Novavax Update (4-2-13)
Apr 182013
 
Novavax Update (4-2-13)

NovaVax released positive Phase II data from their respiratory syncytial virus (RSV) vaccine development candidate, RSV-F.  RSV-F exhibited a robust antibody response and clean safety profile in the trial that enrolled 330 women of childbearing age. The trial is a major step towards the commercial viability of the very first RSV vaccine candidate ever for use […]

Novavax Update (1-25-13)

 Comments Off on Novavax Update (1-25-13)
Jan 252013
 
Novavax Update (1-25-13)

NVAX has cleared an important hurdle tied to the government funding for their seasonal and pandemic flu vaccine program.  The U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has completed an In-Process Review of the company’s contract.   Subsequently, BARDA has notified NVAX that a milestone decision has been made to […]

Novavax Update (11-02-12)

 Comments Off on Novavax Update (11-02-12)
Nov 022012
 
Novavax Update (11-02-12)

NovaVax announced that it has raised a total of $27 million through the sale of 12,285,321 shares of its common stock to RA Capital Management, Camber Capital Management and Ayer Capital Management at a price of $2.18 per share. The shares were offered under an effective shelf registration statement previously filed with the Securities and […]